Неконтрацептивные эффекты комбинированных оральных контрацептивов: преимущества и риски применения


Цитировать

Полный текст

Аннотация

Настоящая публикация посвящена одному из наиболее актуальных направлений гинекологической практики - применению комбинированных оральных контрацептивов (КОК) с учетом их положительных неконтрацептивных свойств. Детально отражен вопрос о том, как с пользой для репродуктивного здоровья женщины использовать КОК, с чем их комбинировать и как провести профилактику рисков, связанных с приемом гормональных препаратов. Информация представлена в виде аналитического обзора международных исследований в отношении преимуществ и рисков применения КОК.

Об авторах

А Л Унанян

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России

Email: 9603526@mail.ru
д-р мед. наук, проф. каф. акушерства и гинекологии №1 ФГАОУ ВО «Первый МГМУ им. И.М.Сеченова» 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2

А Д Никонец

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России

студент ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2

Л Н Аминова

Клиническая больница МЕДСИ

канд. мед. наук, глав. специалист по гинекологии, зав. отд-нием гинекологии КБ МЕДСИ 125284, Россия, Москва, 2-й Боткинский пр., д. 5

В А Алимов

Клиническая больница МЕДСИ

акушер-гинеколог отд-ния гинекологии КБ МЕДСИ 125284, Россия, Москва, 2-й Боткинский пр., д. 5

Ю В Чушков

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России

канд. мед. наук, доц. каф. акушерства и гинекологии №1 ФГАОУ ВО «Первый МГМУ им. И.М.Сеченова» 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2

А В Щукина

ГБУЗ «Городская поликлиника №68» Департамента здравоохранения г. Москвы

зав. женской консультацией ГБУЗ ГП №68 119180, Россия, Москва, ул. Малая Якиманка, д. 22, стр. 1

Е А Кудрина

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России

д-р мед. наук, проф. каф. акушерства и гинекологии №1 ФГАОУ ВО «Первый МГМУ им. И.М.Сеченова» 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2

Д В Бабурин

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России

ассистент каф. акушерства и гинекологии №1 ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2

Список литературы

  1. Hannaford P.C, Iversen L, Macfarlane T.V et al. Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners’ Oral Contraception Study. BMJ 2010; 340: 927.
  2. Прилепская В.Н., Межевитинова Е.А., Иванова Е.В., Сасунова Р.А. Контрацепция и возможности персонифицированного подхода к ее назначению в различные возрастные периоды женщины. Фарматека. 2014; 4: 6-10.
  3. Vodstrcil L.A, Hocking J.S, Law M et al. Hormonal Contraception Is Associated with a Reduced Risk of Bacterial Vaginosis: A Systematic Review and Meta - Analysis. PLoSOne 2013; 8 (9): e73055.
  4. Jarosik G.P, Land C.B, Duhon P et al. Acquisition of iron by Gardnerella vaginalis. Infect Immun 1998; 66 (10): 5041-7.
  5. Sammon C.J, Nazareth I, Petersen I. Recording and treatment of premenstrual syndrome in UK general practice: a retrospective cohort study. BMJ Open 2016; 6 (3): e010244.
  6. Lopez L.M, Kaptein A.A, Helmerhorst F.M. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2012; 2: CD006586.
  7. Lundin C, Danielsson K.G, Bixo M et al. Combined oral contraceptive use is associated with both improvement and worsening of mood in the different phases of the treatment cycle-A double - blind, placebo - controlled randomized trial. Psychoneuroendocrinology 2017; 76: 135-43.
  8. Roberts S.C, Little A.C, Burriss R.P et al. Partner choice, relationship satisfaction, and oral contraception: the congruency hypothesis. Psychol Sci 2014; 25 (7): 1497-503.
  9. Zethraeus N, Dreber A, Ranehill E et al. Combined Oral Contraceptives and Sexual Function in Women - a Double - Blind, Randomized, Placebo - Controlled Trial. J Clin Endocrinol Metab 2016; 101 (11): 4046-53.
  10. Azar-Ramos R. Incidence of side effects with contraceptive placebo. Am J Obstet Gynecol 1989; 105: 1144-9.
  11. Heikinheimo O, Fraser I. The current status of hormonal therapies for heavy menstrual bleeding. Best Pract Res Clin Obstet Gynaecol 2017; 40: 111-20.
  12. Heikkinen S, Koskenvuo M, Malila N et al. Use of exogenous hormones and the risk of breast cancer: results from self - reported survey data with validity assessment. Cancer Causes Control 2016; 27 (2): 249-58.
  13. Moroni R.M, Martins W.P, Dias S.V et al. Combined oral contraceptive for treatment of women with uterine fibroids and abnormal uterine bleeding: a systematic review. Gynecol Obstet Invest 2015; 79 (3): 145-52.
  14. Davis A.R, Westhoff C, O’Connell K et al. Oral contraceptives for dysmenorrhea in adolescent girls: a randomized clinical trial. Obstet Gynecol 2005; 106: 97-104.
  15. Momoeda M, Hayakawa M, Shimazaki Y et al. Does the presence of coexisting diseases modulate the effectiveness of a low - dose estrogen/progestin, ethinylestradiol/drospirenone combination tablet in dysmenorrhea? Reanalysis of two randomized studies in Japanese women. Int J Womens Health 2014; 6: 989-98.
  16. Tafi E, Leone Roberti Maggiore U, Alessandri F et al. Advances in pharmacotherapy for treating endometriosis. Exp Opin Pharmacother 2015; 16: 2465-83.
  17. Benagiano G, Guo S.W, Bianchi P et al. Pharmacologic treatment of the ovarian endometrioma. Expert Opin Pharmacother 2016; 17 (15): 2019-31.
  18. Vercellini P, De Matteis S, Somigliana E et al. Long - term adjuvant therapy for the prevention of postoperative endometrioma recurrence: a systematic review and meta - analysis Acta Obstet Gynecol Scand 2013; 92: 8-16.
  19. Wu L, Wu Q, Liu L. Oral contraceptive pills for endometriosis after conservative surgery: a systematic review and meta - analysis. Gynecol Endocrinol 2013; 29 (10): 883-90.
  20. Seracchioli R, Mabrouk M, Frascà C et al. Long - term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: A randomized controlled trial. Fertil Steril 2010; 93: 52-6.
  21. Zorbas K.A, Economopoulos K.P, Vlahos N.F. Continuous versus cyclic oral contraceptives for the treatment of endometriosis: a systematic review. Arch Gynecol Obstet 2015; 292: 37-43.
  22. Troncon J.K, Neto O.B, Nogueira A.A, Rosae Silva J.C. Continuous or cyclic contraceptives for endometriosis: a question still without an answer. Arch Gynecol Obstet 2015; 292: 481-2101.
  23. Muzii L, Di Tucci C, Achilli C et al. Continuous versus cyclic oral contraceptives after laparoscopic excision of ovarian endometriomas: a systematic review and metaanalysis. Am J Obstet Gynecol 2016; 214: 203-11.
  24. Grimes D.A, Jones L.B, Lopez L.M, Schulz K.F. Oral contraceptives for functional ovarian cysts. Cochrane Database Syst Rev 2014; 4: CD006134.
  25. Rodney J.P, Sataloff R.T. The Effects of Hormonal Contraception on the Voice: History of Its Evolution in the Literature. J Voice 2016; 30 (6): 726-30.
  26. Zimmerman Y, Eijkemans M.J, Coelingh Bennink H.J et al. The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta - analysis. Hum Reprod Update 2014; 20 (1): 76-105.
  27. Somani N, Turvy D. Hirsutism: an evidence - based treatment update. Am J Clin Dermatol 2014; 15 (3): 247-66.
  28. Dokras A. Non contraceptive use of oral combined hormonal contraceptives in polycystic ovary syndrome - risks versus benefits. Fertil Steril 2016; 106 (7): 1572-9.
  29. Adeniji A.A, Essah P.A, Nestler J.E, Cheang K.I. Metabolic Effects of a Commonly Used Combined Hormonal Oral Contraceptive in Women With and Without Polycystic Ovary Syndrome. J Womens Health (Larchmt) 2016; 25 (6): 638-45.
  30. Gallo M.F, Lopez L.M, Grimes D.A et al. Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2014; 1: CD003987.
  31. Caprio M, Antelmi A, Chetrite G. Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome. Endocrinology 2011; 152 (1): 113-25.
  32. Sitruk-Ware R, Nath A. Characteristics and metabolic effectsof estrogen and progestins containedin oral contraceptive pills. Pract Res Clin Endocrinol Metab 2013; 27: 13-24.
  33. Lopez L.M, Grimes D.A, Schulz K.F. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev 2014; 4: CD006133.
  34. Roura E, Travier N, Waterboer T et al. The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre - Cancer: Results from the EPIC Cohort. PLoSOne 2016; 11 (1): e0147029.
  35. Havrilesky L.J, Gierisch J.M, Moorman P.G et al. Oral contraceptive use for the primary prevention of ovarian cancer. Evid Rep Technol Assess (FullRep) 2013; 212: 1-514.
  36. Moorman P.G, Havrilesky L.J, Gierisch J.M et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high - risk women: a systematic review and meta - analysis. J Clin Oncol 2013; 31 (33): 4188-98.
  37. Iversen L, Sivasubramaniam S, Lee A.J, Fielding S et al. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study. Am J Obstet Gynecol 2017. pii: S0002-9378(17)30179-5.
  38. Wu L, Zhu J. Linear reduction in thyroid cancer risk by oral contraceptive use: a dose - response meta - analysis of prospective cohort studies. Hum Reprod 2015; 30 (9): 2234-40.
  39. Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: an individual participant meta - analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol 2015; 16 (9): 1061-70. doi: 10.1016/S1470-2045(15)00212-0. Epub 2015 Aug 4.
  40. Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R, Hermon C et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008; 371 (9609): 303-14. doi: 10.1016/S0140-6736(08)60167-1.
  41. Mc Laughlin J.R, Risch H.A, Lubinski J et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case - control study. Lancet Oncol 2007; 8 (1): 26-34.
  42. The World Health Organization. Medical eligibility criteria for contraceptive use. Fifth edition. Contraception 2016; 94 (3): 193-4.
  43. Tepper N.K, Whiteman M.K, Zapata L.B et al. Safety of hormonal contraceptives among women with migraine: A systematic review. Contraception 2016; 94 (6): 630-40.
  44. Practice Committee of the American Society for Reproductive Medicine. Combined hormonal contraception and the risk of venous thromboembolism: a guideline. Fertil Steril 2017; 107 (1): 43-51.
  45. Stegeman B.H, de Bastos M, Rosendaal F.R et al. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta - analysis. BMJ 2013; 347: f5298.
  46. de Bastos M, Stegeman B.H, Rosendaal F.R et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev 2014; 3: CD010813.
  47. Plu-Bureau G, Maitrot-Mantelet L, Hugon-Rodin J, Canonico M. Hormonal contraceptives and venous thromboembolism: an epidemiological update. Best Pract Res Clin Endocrinol Metab 2013; 27: 25-34.
  48. Bird S.T, Delaney J.A, Etminan M et al. Drospirenone and non - fatal venous thromboembolism: is there a risk difference by dosage of ethinyl - estradiol? J Thromb Haemost 2013; 11: 1059-68.
  49. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of combined oral contraceptives and risk of venous thromboembolism: nested case - control studies using the QResearch and CPRD databases. BMJ 2015; 350: h2135.
  50. Ziller M, Ziller V, Haas G et al. Risk of venous thrombosis in users of hormonal contraceptives in German gynaecological practices: a patient database analysis. Arch Gynecol Obstet 2014; 289: 413-9.
  51. Sidney S, Cheetham T.C, Connell F.A et al. Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users. Contraception 2013; 87: 93-100.
  52. Bateson D, Butcher B.E, Donovan C et al. Risk of venous thromboembolism in women taking the combined oral contraceptive: A systematic review and meta - analysis. Aust Fam Physician 2016; 45 (1): 59-64.
  53. Van Hylckama Vlieg A, Helmerhorst F.M, Vandenbroucke J.P et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case - control study. BMJ 2009; 339: b2921.
  54. Amoozegar F, Ronksley P.E, Sauve R, Menon B.K. Hormonal contraceptives and cerebral venous thrombosis risk: a systematic review and meta - analysis. Front Neurol 2015; 6: 7.
  55. Roach R.E, Helmerhorst F.M, Lijfering W.M et al. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Data base Syst Rev 2015; 8: CD011054.
  56. Sugiura K, Kobayashi T, Ojima T. Risks of thromboembolism associated with hormonal contraceptives related to body mass index and aging in Japanese women. Thromb Res 2016; 137: 11-6.
  57. Инструкции по медицинскому применению препаратов Курантил® N25(ПN013897/01-280312), Курантил® N75 (ПN013899/01-280312).
  58. Eisert W.G. Dipyridamole in antithrombotic treatment. Adv Cardiol 2012; 47: 78-86.
  59. Goda A.E, Yoshida T, Horinaka M, Yasuda T. Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole. Oncogene 2008; 27 (24): 3435-45.
  60. Choudhary S, Sood S. Dipyridamole intervention of breast cell carcinogenesis. Mol Carcinog 2014; 53 (3): 243-52.
  61. Kowalska K, Milnerowicz H. Pro/antioxidant status in young healthy women using oral contraceptives. Environ Toxicol Pharmacol 2016; 43: 1-6.
  62. Chen J.T, Kotani K. Oral contraceptive therapy increases oxidative stress in pre - menopausal women. Int J Prev Med 2012; 3 (12): 893-6.
  63. Ciacciarelli M, Zerbinati C, Violi F, Iuliano L. Dipyridamole: a drug with unrecognized antioxidant activity. Curr Top Med Chem. 2015; 15 (9): 822-9.
  64. Balakumar P, Nyo Y.H, Renushia R, Raaginey D. Classical and pleiotropic actions of dipyridamole: Not enough light to illuminate the dark tunnel? Pharmacol Res 2014; 87: 144-50.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО "Консилиум Медикум", 2017

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).